PubMed Health⌕ Search

Biomedical subjects

L H Baker

Publications and source records attributed to L H Baker.

169 records · Page 10Linked to original sources
PubMedDate not supplied

Mitomycin C and bleomycin in the treatment of far-advanced cervical cancer: a Southwest Oncology Group pilot study.

Under the auspices of the Southwest Oncology Group, Wayne State University tested a schedule using bleomycin and mitomycin C that was previously reported to give a response rate of 88%. In our patients the same regimen produced similar toxic effects but a far different response rate of 15.8% (one complete remission and two partial remissions). The only discernible difference in the two patient groups was the amount of radiation given prior to chemotherapy.

Bleomycin↗
PubMedDate not supplied

Phase II study of AMSA in lung cancer.

Ninety-one assessable patients with advanced oat cell and non-oat cell carcinoma of the lung were given AMSA on an intermittent every-3-week schedule. Starting doses ranged from 55 to 120 mg/m2, depending on the presence and severity of hepatic dysfunction. Three partial responses (two squamous cell carcinomas, one adenocarcinoma) of short duration were documented. The major toxic effect was leukopenia (44%). AMSA does not appear to have sufficient antitumor activity to warrant further investigation in advanced lung cancer.

Adenocarcinoma↗
PubMedDate not supplied

Combination chemotherapy with cyclophosphamide, vincristine, methyl-CCNU, and bleomycin in advanced bronchogenic carcinoma: experience with 106 patients.

A phase II study was conducted with three different combinations of cyclophosphamide, Oncovin (vincristine), methyl-CCNU, and bleomycin (COMB) in 106 patients with advanced bronchogenic carcinoma of all histologies. The response rates were 27.3% for COMB I (six of 22 patients), 18.2% for COMB II (eight of 44 patients), and 7.5% for vincristine, methyl-CCNU, and bleomycin (three of 40 patients). Complete responses were seen only in the small cell carcinoma group. Duration of remission and overall survival were of significance for the small cell group, whereas survival for the other histologic types comparing responders to nonresponders was of no statistical significance. Toxicity was significant and included nausea and vomiting, neuropathy, and myelosuppression. These drug combinations were disappointing and only in small cell carcinoma was meaningful antitumor activity seen.

Antineoplastic Agents↗
PubMedDate not supplied

Phase II trial cisplatin, doxorubicin, and cyclophosphamide (CAP) in the treatment of urothelial transitional cell carcinoma.

Patients with advanced transitional cell cancer of the bladder, urethra, or renal pelvis were treated with a combination of cyclophosphamide, doxorubicin, and cisplatin. Fifteen patients were evaluated, 12 of whom had cancer of the urinary bladder. Metastatic sites were bone (47% of the patients); lung (33%) pelvis (27%); liver (20%); nodes (7%); and brain (7%). Only two patients (13%) achieved a partial response (in measurable node and lung lesions) and survived 16 and 58 weeks. Three patients (20%) had minor responses (in measurable bone, pelvis mass, and bone and local lesions) and survived 8, 28, 102+ weeks, respectively. Four patients had stable disease and six had disease progression, with a median survival of 4 weeks. Overall toxic effects were leukopenia (53% of the patients); thrombocytopenia (27%); nausea and vomiting (67%); alopecia (60%); and renal (13%). We concluded that the response rate to the combination of cyclophosphamide, doxorubicin, and cisplatin in transitional cell cancer of the urothelium was not superior to the reported response rate ot a single agent (eg, cisplatin), and toxicity was greater.

Carcinoma, Transitional Cell↗
PubMedDate not supplied

Retention of esthetic veneers on primary stainless steel crowns.

The purpose of this study was to ascertain the amount of shearing force necessary to fracture, dislodge or deform the esthetic veneer facings of four commercially available veneered primary incisor stainless steel crowns. The four types tested were: Cheng Crowns, [Peter Cheng Orthodontic Laboratory]; Whiter Biter Crown II, [White Bite Inc.]; Kinder Krowns, [Mayclin Dental Studio, Inc]; and NuSmile Primary Crowns, [Orthodontic Technologies, Inc]. The crowns (#4 right central incisor) from each manufacturer were obtained with the facings attached. The crowns were soaked for ninety days and thermocycled at 4 degrees C and 55 degrees C for 500 45-second cycles. The crowns were cemented to standardized chromium cobalt metal dies. Each die was placed in to a custom holder on the Instron Universal testing machine. A force was applied at the incisal edge of the veneer at 148 degrees, (the primary interincisal angle), with a crosshead speed of 0.05 inches/minute until the veneer either fractured, dislodged or deformed. The mean force (Ibs) required +/- SD to produce failure, in descending order, was as follows: Cheng (107.8 +/- 17.3); NuSmile (100.2 +/- 18.2); KinderKrown (91.3 +/- 27.4)d Whiter Biter (81.5 +/- 21.7). To test the hypothesis of no difference among the four manufacturers, an analysis of variance was performed using PROC GLM. The resultant F statistic was 2.79 (p < 0.0543), indicating a marginally statistically significant difference in the response variable "pressure" among the four groups. A posthoc test was then performed to ascertain where these differences occurred. These results, using Turkey's studentized range test for pairwise comparisons, suggested that the only difference was between the Cheng and Whiter Biter manufacturers.

Analysis of Variance↗